These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1431 related articles for article (PubMed ID: 33907095)

  • 41. False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy.
    Chimenti C; Alfarano M; Maestrini V; Galea N; De Vincentis G; Verardo R; Fedele F; Frustaci A
    ESC Heart Fail; 2021 Aug; 8(4):3387-3391. PubMed ID: 34032384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multimodality assessments of wild-type transthyretin cardiac amyloidosis with no ventricular hypertrophy.
    Iwaya T; Okada A; Tateishi E; Ohta Y; Morita Y; Ohta-Ogo K; Izumi C
    ESC Heart Fail; 2023 Apr; 10(2):1412-1417. PubMed ID: 36335980
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.
    Treibel TA; Fontana M; Gilbertson JA; Castelletti S; White SK; Scully PR; Roberts N; Hutt DF; Rowczenio DM; Whelan CJ; Ashworth MA; Gillmore JD; Hawkins PN; Moon JC
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27511979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis.
    Gawor M; Holcman K; Franaszczyk M; Lipowska M; Michałek P; Teresińska A; Bilińska ZT; Rubiś P; Kostkiewicz M; Szot W; Podolec P; Grzybowski J
    Cardiol J; 2022; 29(6):985-993. PubMed ID: 32789836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.
    Xin Y; Hu W; Chen X; Hu J; Sun Y; Zhao Y
    Hellenic J Cardiol; 2019; 60(6):375-383. PubMed ID: 30742933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser.
    Lai HJ; Huang KC; Liang YC; Chien KL; Lee MJ; Hsieh ST; Chao CC; Yang CC
    J Formos Med Assoc; 2020 Mar; 119(3):693-700. PubMed ID: 31521469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute cardiac failure secondary to senile systemic amyloidosis.
    Bodard Q; Roca F; Dilly B; Laurent D; Chassagne P
    Age Ageing; 2016 Nov; 45(6):908-909. PubMed ID: 27103598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Transthyretin amyloidosis in a cohort of old and very old patients with chronic heart failure].
    Poliakova AA; Semernin EN; Sitnikova MY; Аvagyan KL; Grozov RV; Pyko SA; Krutikov AN; Davydova VG; Khmelnitskaya KA; Shavloskii MM; Korzhevskii DE; Gudkova AY
    Kardiologiia; 2018 SFeb; (S2):12-18. PubMed ID: 29782249
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers.
    Nagano N; Muranaka A; Nishikawa R; Ohwada W; Kouzu H; Kamiyama N; Fujito T; Mochizuki A; Nagahara D; Nakanishi M; Ohkubo Y; Hisahara S; Nakao S; Katoh N; Ishikawa A; Sakurai A; Yano T
    Int Heart J; 2022; 63(1):168-175. PubMed ID: 35095067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
    Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC
    Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus.
    Chander Mohan J; Dalal J; Chopra VK; Narasimhan C; Kerkar P; Oomman A; Ray Fcsi S; Sharma AR; Dougall P; Simon S; Verma Drm A; Radhakrishnan V
    Indian Heart J; 2022; 74(6):441-449. PubMed ID: 36410415
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transthyretin-related amyloidoses and the heart: a clinical overview.
    Rapezzi C; Quarta CC; Riva L; Longhi S; Gallelli I; Lorenzini M; Ciliberti P; Biagini E; Salvi F; Branzi A
    Nat Rev Cardiol; 2010 Jul; 7(7):398-408. PubMed ID: 20479782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
    Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
    Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.